Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Objective: To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes.

[1]  E. Round,et al.  Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis , 2008, BMC endocrine disorders.

[2]  S. Dejager,et al.  Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes , 2007, Diabetologia.

[3]  M. Riddle,et al.  Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. , 2005, Diabetes care.

[4]  K. Hermansen,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.

[5]  Toxicity of hyperglycaemia in type 2 diabetes. , 1998, Diabetes/metabolism reviews.

[6]  A. Karasik,et al.  Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. , 2008, Current medical research and opinion.

[7]  J. Levy,et al.  Changes in Amylin and Amylin-Like Peptide Concentrations ana (β-Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM , 1998, Diabetes Care.

[8]  D. Owens,et al.  Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial , 2008, The Lancet.

[9]  C. Cobelli,et al.  Insulin Secretion Rate During Glucose Stimuli: Alternative Analyses of C-Peptide Data , 2001, Annals of Biomedical Engineering.

[10]  W. Herman,et al.  Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. , 2006, Diabetes care.

[11]  H. Bilo,et al.  Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients , 2008, Diabetes Care.

[12]  J. Rosenstock,et al.  Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia , 2009, Diabetes, obesity & metabolism.

[13]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[14]  Ronald Brazg,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.

[15]  M. Davies,et al.  Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. , 2005, Diabetes care.

[16]  M. Korytkowski,et al.  When oral agents fail: practical barriers to starting insulin , 2002, International Journal of Obesity.

[17]  Robert A Gabbay,et al.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. , 2005, Diabetes care.

[18]  A. Farmer,et al.  Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. , 2007, The New England journal of medicine.

[19]  F. Pi‐Sunyer,et al.  The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight , 2008, Postgraduate medicine.

[20]  C. Cobelli,et al.  Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[21]  H. Yki-Järvinen,et al.  Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study , 2006, Diabetologia.

[22]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[23]  C. Cobelli,et al.  Effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on beta‐cell function in patients with type 2 diabetes: a model‐based approach , 2008, Diabetes, obesity & metabolism.

[24]  J. Leahy,et al.  Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .

[25]  P. Nilsson,et al.  Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[27]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[29]  L. Kennedy.  A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes , 2007 .

[30]  E. Ryan,et al.  Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. , 2004, Diabetes care.

[31]  J. Vaz,et al.  Intensification lessons with modern premixes: from clinical trial to clinical practice. , 2008, Diabetes research and clinical practice.

[32]  Dennis D. Kim,et al.  A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study , 2007, Diabetologia.